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Schizophrenia : General
Findings and Current status
Amresh Shrivastava
Mumbai

Genetic Risk Of Schizophrenia
General population
Second degree Relative
Parents
Sibling
Child, 1 parent
Child, 2 parents
Twin Monozygotic

1%
2.5%
3.8%
8.7%
12%
30-40%
40-50%

Risk factors for schizophrenia

Genetics
Pre-or-perinatal events
Factors during childhood
and adolescence

Psychological and
electrophysiological
characteristics of schizophrenia

Cognitive dysfunction
Neurophysiologic
dysfunction

1%

5%

Schizophrenia

Schizophrenia-related
Personality Disorders

Brain Structure and
Function in schizophrenia

Brain Structure
Brain Function

Theories of schizophrenia
Dopamine
Neuronal System
Neurodevelopmental factors
Limbic structures

Postmortem studies in
schizophrenia
Established by systematic reviews:
Enlargement of lateral and third ventricles
(+ 25%-40%)
Smaller brain volume (-3%)
Smaller Grey matter volume (-6%)
Relatively smaller medial temporal lobe volume
(-5%)
Relatively smaller thalamic volume (-4%)
Larger basal ganglia( especially globus pallidus)

Characteristics of Structural imaging
findings in schizophrenia
Differences are readily apparent in discordant
monozygotic twins
Differences are present in first-episode,
untreated patients, and high-risk and
unmedicated individuals.
No convincing evidence of heterogeneity
( e.g.. Subtypes or gender differences),
although this remains controversial.
The alterations are not seen in Bipolar Disorder
to the same extent.

Histological findings in schizophrenia.
0 no good evidence, +/- equivocal data,
+ to ++++ increasing amount of supportive

data

finding

Weight of
evidence

Lack of neurodegenerative lesion( eg.Alzheimer
Changes)

+++++

Lack of Gliosis

++++

Smaller cortical hyppocampal pyramidal Neurons

+++

Decreased Cortical and Hippocampal Synaptic
markers

++

Decreased Dendritic Spine Density

++

Loss of Neurons from Dorsal thalmus

++

Abnormalities of white matter neurons

+

Entorhinal Cortex Dysplasia

+

Disarray of hippocampal neuron orientation

+/-

Loss of hippocampal or cortical neurons

0

Histological and Molecular
pathology in Schizophrenia
Gliosis & Neurodegeneration
Neuronal Cytoarchitecture
Synapse & dendrites.
Location and extent of pathology

Neurochemistry of schizophrenia
Dopamine
Serotonin
Glutamate
Gama-aminobutyric acid ( GABA)

Dopamine
Main postmortem
Findings
Increased Density of D2
receptors
Decreased Cortical DA
innervation
Increased D4 –like
receptor binding
Alteration in D3 receptor
splicing

Other supportive
evidence
DA – releasing agent
produce psychosis
All antipsychotics are D2
Receptor antagonists
Increased striatal DA
release in vivo

Glutamate
Main Postmortem findings
Decreased presynaptic
markers

Other supportive evidence

NMDA receptor antagonists
produce schizophrenia-like
psychosis
Decreased HC AMPA and
Roles of NMDA in
kinetic receptor expression development and
neurotoxicity
Minor changes in FC NMDA Partial NMDA agonists have
receptor subunits
some therapeutic benefits
Altered Glutamate fibers in
cingulate cortex

5-HT
Main Postmortem
findings

Other supportive
evidence

Decreased FC 5-HT 2Areceptor
expression

5-HT 2 agonists e.g. LSD are
psychotomimetic

Increased FC 5-HT 1A receptors

5-HT 2 receptor polymorphism
associated with schizophrenia and
clozapine response

Increased 5-HT transporter affinity

Atypical antipsychotics have high
affinity for several 5-HT receptors

Developmental and trophic role of
5-HT

GABA
Main Postmortem findings

Other supportive
evidence

Decreased base density of FC GABAergic
terminals

Role of GABA in
stress and
Neurotoxicity

Increased GABA,A receptor subunits
Increased GABA , A , receptor binding in limbic
areas
Decreased FC expression of glutamic acid
decarboxylase
Altered density of cingulate GABAergic cells

Some questions
for postmortem studies
Which of the cytoarchetectural and synaptic alterations
are robust?
Is there a single pathology or several?
How are the structural and neurochemical findings
related?
Does the neuropathology underlie the aberrant
functional connectivity?
Does the neuropathology relate to psychotic
symptoms or cognitive deficits?
Are the changes diagnostically specific?

Dopamine in schizophrenic brain
Brain Imaging as a tool for measuring DA
synaptic activity.
Imaging amphetamine-induced DA release in
Schizophrenia.
Imaging baseline DA activity in schizophrenia.
Cortical Regulation of subcortical DA
transmission
Schizophrenia and endogenous sensitization.
DA hyperactivity, neuroplasticity, and positive
symptoms.
Implications for treatment

Gene

Neurodevelopmental
abnormality

Developmental Insult

Deficient cortical control
Of Subcortical DA activity

Stress

Increased subcortical DA release
( stress-related)
Endogenous
sensitization
Sustained Subcortical DA release
(Non Stress-Related)

Altered information flow
In corticostriatothalamocortical loops
(DA-Dependent)
Long term plasticity

(-)
Treatment

Psychotic episode
( treatment-Responsive)

No
Treatment
Chronic Psychotic State
( Treatment- unresponsive)

Q1. Whether the disease would
develop or NOT?
Q2. If so, when?
Q3.whether it would be treatment
responsive or resistant?
Q4.If treatment responsive ,Will it
Relapse or NOT?

Only partly answered
Genetic loading
Developmental Insult
Genetic Expression : time, speed,
specificity, partial/ complete
expression.
Stress factors
Biochemical dysregulation
Neuronal plasicity

Violence in schizophrenia
Where is the evidence?
Predicting violence
Clinical implications

Predictors of violence common to
patients with clinically stable
schizophrenia and the General
population
Sociodemographic factors( age, gender,
economic status and unemployment)
Drug abuse
Antisocial personality
Family history of violence
Previous violence

Clinical predictors of violence in
schizophrenic patients with exacerbation
of psychotic symptoms
Type and characteristic of delusions.
-delusions causing fear and anguish.
- persecutory delusions
- active seeking of information to confirm or refute the
delusional belief.
- systematization and conviction of the delusion
- quality of hallucination
Previous violence
Less insight into symptoms
Higher PANSS general psychopathology score

Approach to reducing
noncompliance
Use of depot medications
Patient recognition of need of treatment
Close monitoring to adherence.
Use of drugs with better side-effect
profiles.
Subjective experience.

Future actions
Treatment programme that are effective in prevention of
violence.
Investigation of the variables associated with violence
that are amenable to therapeutic approaches.
Strategies to increase compliance with treatment.,which
may translate into a reduction in number of violent
episodes and fewer psychotic relapses.
Treatment reducing poor impulse control.
Competent well developed community support and
comprehensive mental health follow up to identify and
successfully deal with early signs of violent behaviour.
Development of validated instruments for assessment of
future violence

To minimize SE

Conventional Antipsychotics
Lowering the Dose
Decreases SE

Not effective in 50% & in NS;
SE, EPS, TD, PRL,NMS

SE contributes to treatment
nonadherence

Relapse

Rehospitalization

decreases Efficacy
& Relapse
CAPD do not reduce
all symptoms and
& disability in
Schizophrenia.
At least 50% patients live
with persistent, residual
Symptoms;
at least 20% relapse
Despite adequate doses.
substantial % continue
as severely disabled,
frequently relapse,

Conventional antipsychotics
Despite substantial data from controlled
trials that support the efficacy of CAPD for
the positive symptoms, the effectiveness of
these agents in everyday clinical practice is
substantially less than their efficacy as
determined by controlled trials.
Although many factors may be involved,
we do not know all the causes of this

Efficacy-effectiveness gap

Antipsychotics:
Second generation
Action of CAPD involves D2 blockade in
limbic system and striatum.
Receptor blockade in limbic system is basis
for antipsychotic action.
Reduction of activity in striatum is related to
EPS & TD.
D2 blockade of HPA-axis leads to
hyperprolactaemia.

Antipsychotics:
Second generation
Newer drugs have lesser affinity to D2;
and greater affinity to other receptors
like 5 HT,NA [alpha 1 & 2],
ability to modulate glutamate receptormediated functions and behavior.

Antipsychotics: Second generation
Typical characteristic of atypicals is a ‘low
D2 & 5- HT Ratio’.
There is some degree of regional anatomical
specificity. [very little effect on corpus
striatum].
Various claims have lead to a debate.
Question of well-being of millions suffering
from schizophrenia and a billion dollars of
costs.
If the additional cost of atypical is justified by
potential benefit? To influence clinicians and
policy makers.

Antipsychotics:
Second generation
Claim of superior efficacy and
safety have been made but ‘the
evidence’ is variable and often
‘inadequate’.

There is now strong evidence that AAPD
are efficacious and have less SE [ low risk
of EPS ] than CAPD.
However, comprehensive understanding of
nature and extent of any ‘clinical
advantages’ of AAPD over CAPD, is not
available.
( Leucht S, et al , Aust. N Z J.Psychiat.1998).

The advantage of EPS and TD might
be offset by disadvantage of other
SE e.g. weight gain, DM, glucose
metabolism, hyperlipidaemia

Existing studies have found that atypical
antipsychotics cause fewer EPSs side effects
than their conventional counterparts,
especially when the conventional comparator
is haloperidol.
In spite of marketing claims, studies of effect
on cognitive functions are wholly
inconclusive, as are effect on mood
symptoms.

The effects of AAPD on
Long-term outcome
Relapse prevention
Social and vocational functioning
Suicide prevention
Quality of life
Family and caregivers burden

Have just begun to be explored

Risperidone, olanzapine and Quetiapine
account for > 50% of the prescriptions
of New Antipsychotics in North
America.
The rate of usage in other countries
varies from 5% to 40% .

Usage - AAPD
Patients who had inadequate response to
conventional antipsychotics or who suffered
problematic side effects are the first to be
switched to atypical APD.
Now, however , many newly diagnosed or
first-episode patients are initially prescribed
these newer agents with the hope ( not yet
backed by evidence ) of giving them very
early advantage.[ Lieberman JA, JCP, 1996]

Atypical agents are several time more
expansive, average being $ 5000 or more per
patient per year.
Even if atypical antipsychotic drugs do not
decrease the overall cost of care, their usage
may be warranted if their benefits are judged
to be substantial enough to justify the
increased expenditure.
Currently the cost-effective
justification,
.
in scarce resources of public health,
does not hold valid

The clinical and public policy decision to
supplant conventional with atypical APD
requires empirical evidence.
This is important because the spending of
large sum of money on treatments that are
less cost-effective than available alternatives
may result in needless waste of scarce
resources and deprive some patients of
clinical benefits to which they would
otherwise have access.

The evidence to support the superior
effectiveness of atypical APD is currently
limited and predominantly based on short-term
efficacy studies.
Existing evidence does not adequately
address the long-term effectiveness and cost
issue.
Studies designed to obtain FDA permission [
6-8 weeks trials] do not definitively
demonstrate “the real World” effect of
AAPD.

Schizophrenia : Family Studies and
Treatment of spectrum disorders.
Eversince the disease was described by Kraepeline, 100
years back, treatments have been in progress.Major
advances are noticed That:
Treatment of schizophrenia and other mental disorders
have become more Humane and now alinged more
closely to other medical disorders.
Antipsychotics have become the first line of defence ,and
have improved the lives of most patients.
A greater understanding of the genetic basis of
schizophrenia underlies much of the recent progess, in
part through its focus on reliable diagnosis.

One consequence of Genetic studies is the
recognition that schziophrenia illness is broader
than the DSM or ICD diagnosis of schziophrenia,
and exists as a “ Spectrum” of conditions.
While some spectrum disorders are as severe
as schizophrenia like schizo-affective disorder,
others are milder and do not involve psychosis
eg. Schizoptypal personality disorder [ SPD]

The spectrum concept has
numerous implications for
treatment.

Therapeutic efforts vary across schizophrenia
spectrum disorders as function of both severity
and type of symptoms.
These differences are of grate importance in
understanding the core features of
schizophrenia.
Fact that ‘psychosis is not a major feature of
spectrum disorder’ suggests that other more
subtle symptoms might better reflect underlying
etiology.

If such deficits are identifiable, they
may provide foundation for treatment
strategies
Moreover, if they are identifiable early,
they may even prevent psychosis.
Discussion on spectrum disorder should
focus on reflections of genetic
predisposition.
There is a need to redefine and
reformulate Meehl’s notion of ‘schizotaxia’.
Scizotaxia is perhaps the core liability for
Schizophrenia and spectrum disorder.

Relatives with
Schizotypal personality
disorder
Relatives with other
Psychotic illness

Relatives with
schziophrenia
Relatives with
Psychotic affective
disorder
Relatives with
Alcoholism
Comorbid
schizophrenia

Relatives with schizophrenia
Spectrum disorder

Family
studies
The relatives

Normal –
asymptomatic

Relatives with
Nonpsychotic
illness

Relatives with
Mood Disorder

Schziophrenic
patient

Relatives with
other
Psychiatric illness
Relatives with
alcoholism

Lessions from family studies of nonpsychotic
relatives of schizophrenic illness
Progress in identification of neuropsychological and
structural brain abnormalities in the relatives.[ mainly first
–degree ].Data show :(i) relatively specific N-Psy. deficits in both, patients and
their relatives.
(ii) the stability of these deficits over time.
(iii) the structural and functional brain abnormalities in
patients and relatives.
(iv) the effect of genetic loading on N-Psych. Functions
and neuroanatomical structures.

These findings form foundation of current
efforts to define, validate and treat ‘schizotaxia’

Neuropsychological functions among
adult relatives : functions studied
1.
2.
3.
4.
5.

Abstraction /
executive memory
Verbal ability
Spatial ability
Verbal memory
Visual memory

6. Verbal memory
7.Learning
8.Perceptual-motor
speed
9.Mental
control/encoding
10.Motor functions
11.Auditory attention

Findings in controlled studies
The relatives performed more poorly and had greater
variability on three predicted functions :
1.abstarction/ executive function.2.verbal memory
3.auditory attention/vigilance .
Lower scores on mental control and verbal ability.
Showed more variability on learning and motor
ability.
Two groups did nor differ on visual ability, visual
memory, or perceptual motor function.
The deficits observed did not account for by
psychopathology in relatives, by level of education
or parental social class.

Findings in controlled studies
Neuropsychological measures might be useful in
detecting putative carriers of the schizophrenia
genotype, who cannot be detected with psychiatric
assessment.
These are at best the ‘ risk indicators for underlying
vulnerability to schziophrenia.
It could be hypothesised that ,if the expression of
neuropsychological risk indicators in the relatives was
due to an underlying genotype ,then the
neuropsychological indicators of schziophrenia
genotype would intercorrelate to a greater degree within
the relative’s group.
Men with schizophrenia have greater degree of
neuropsychological deficits that women.

Stability of neuropsychological
deficits

Schizophrenia and spectrum Disorder:
Genetic phenomenology
Decreasing Genetic Risk
for schizophrenia in
Relatives

Schizophrenia

Increasing Genetic Risk
for affective Disorders
and alcoholism in Relatives

1%

1%

1%
1%

Affective
schizophrenia

1%
0.7%

Core/ deficit
Schizophrenia

1%
1%
Schizotypal
Personality
Disorder

